An Open-label Extension of a Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate Simvastatin 20 mg Plus Omacor 4g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia
Latest Information Update: 05 Jun 2025
At a glance
- Drugs Omega-3-acid ethyl esters (Primary) ; Simvastatin
- Indications Dyslipidaemias
- Focus Therapeutic Use
Most Recent Events
- 29 May 2025 Status changed from active, no longer recruiting to completed.